Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Seattle Genetics’ Adcetris gets FDA priority review for Hodgkin lymphoma
Brentuximab vedotin is an antibody-drug conjugate (ADC) directed to CD30, a marker of classical Hodgkin lymphoma. The FDA is likely to take a call on Adcetris approval by
Brentuximab vedotin is an antibody-drug conjugate (ADC) directed to CD30, a marker of classical Hodgkin lymphoma. The FDA is likely to take a call on Adcetris approval by
The data from the study demonstrated that the three-part drug has improved certain aspects of memory and thinking ability, as well as helped in limited brain changes associated
Atacand is an angiotensin II receptor blocker (ARB) indicated for the treatment of hypertension in adults and children 1 to <17 years of age, to lower blood pressure.
The transaction amount includes Sucampo’s debt of $360m assumed by the UK-based Mallinckrodt. Amitiza (lubiprostone) has the approvals of the US Food and Drug Administration (FDA) for three
The European Commission has approved Alecensa (alectinib) as first-line treatment in ALK-positive lung cancer, while the US Food and Drug Administration (FDA) approved Perjeta (pertuzumab), in combination with Herceptin (trastuzumab) and
The two companies have entered into a collaboration for a phase 1b study to combine TAR-200 (GemRIS) with Bristol-Myers' Opdivo (nivolumab) to treat muscle invasive bladder cancer. The trial will assess
Under the deal, the partners will assess Array's MEK inhibitor binimetinib in combination with Pfizer's investigational PARP inhibitor talazoparib and human anti-PD-L1 IgG1 monoclonal antibody avelumab. They will evaluate
The investigational adeno-associated viral (AAV) vector gene therapy has been approved as a one-time gene therapy for confirmed Biallelic RPE65 mutation-associated retinal dystrophy. Patients having RPE65-mediated inherited retinal disease
Vraylar (cariprazine) is an oral and once daily atypical antipsychotic secured approval for the acute treatment of adult patients with manic or mixed episodes associated with bipolar I
Published in draft guidance, the enforcement priorities are expected to keep a check on certain homeopathic drugs that can be harmful and have no proven medical benefits. The